Mind Medicine (MindMed) Inc. [NASDAQ: MNMD] closed the trading session at $3.74 on 06/18/21. The day’s price range saw the stock hit a low of $3.71, while the highest price level was $3.95. The company report on June 17, 2021 that MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board.
– MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company’s Scientific Advisory Board.
Dr. Bergethon is the Vice President and Head of Digital and Quantitative Medicine at Biogen Inc., where he leads the effort to transform clinical trials and humanize drug discovery by encouraging the transition of clinical trial measures from a qualitative to a quantitative discipline. The Quantitative Medicine transformation has advanced Biogen’s leadership in neuroscience therapeutics and personalized medicine. Dr. Bergethon came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was Vice President and Head of the Pfizer Innovation Research Lab within the Early Clinical Development group.
The stocks have a year to date performance of 22.62 percent and weekly performance of -4.59 percent. The stock has been moved at 15.08 percent over the last six months. The stock has performed 8.72 percent around the most recent 30 days and changed 34.03 percent over the most recent 3-months.
If compared to the average trading volume of 8.84M shares, MNMD reached to a volume of 12676521 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mind Medicine [MindMed] Inc. [MNMD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MNMD shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MNMD stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Mind Medicine (MindMed) Inc. is set at 0.32
MNMD stock trade performance evaluation
Mind Medicine (MindMed) Inc. [MNMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.59. With this latest performance, MNMD shares gained by 8.72% in over the last four-week period, additionally plugging by 15.08% over the last 6 months – not to mention a rise of 1108.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNMD stock in for the last two-week period is set at 55.44, with the RSI for the last a single of trading hit 56.36, and the three-weeks RSI is set at 54.65 for Mind Medicine (MindMed) Inc. [MNMD]. The present Moving Average for the last 50 days of trading for this stock 3.29, while it was recorded at 3.71 for the last single week of trading, and 2.42 for the last 200 days.
Mind Medicine [MindMed] Inc. [MNMD]: An insightful look at the core fundamentals
Return on Total Capital for MNMD is now -79.31, given the latest momentum, and Return on Invested Capital for the company is -86.40. Return on Equity for this stock declined to -86.40, with Return on Assets sitting at -83.88.
Mind Medicine [MindMed] Inc. [MNMD]: Insider Ownership positions
There are presently around $1 million, or 0.57% of MNMD stock, in the hands of institutional investors. The top three institutional holders of MNMD stocks are: TRU INDEPENDENCE LLC with ownership of 167,293, which is approximately 48.45% of the company’s market cap and around 6.56% of the total institutional ownership; GOFEN & GLOSSBERG LLC /IL/, holding 72,500 shares of the stock with an approximate value of $0.27 million in MNMD stocks shares; and FNY INVESTMENT ADVISERS, LLC, currently with $75000.0 in MNMD stock with ownership of nearly New of the company’s market capitalization.
Positions in Mind Medicine (MindMed) Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 5 institutional holders increased their position in Mind Medicine (MindMed) Inc. [NASDAQ:MNMD] by around 93,600 shares. Additionally, 1 investors decreased positions by around 2,249 shares, while 1 investors held positions by with 177,444 shares. The mentioned changes placed institutional holdings at 273,293 shares, according to the latest SEC report filing. MNMD stock had 3 new institutional investments in for a total of 31,000 shares, while 0 institutional investors sold positions of 0 shares during the same period.